Literature DB >> 30287936

Feasibility of Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation.

Nour M Moukalled1, Haidar El Darsa1, Yolla Haibe1, Radwan Massoud1, Souha S Kanj2, Rami Mahfouz3, Ali Bazarbachi4, Jean El-Cheikh5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30287936     DOI： 10.1038/s41409-018-0347-6

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  3 in total

Review 1.  Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?

Authors:  Serena Brancati; Lucia Gozzo; Giovanni Luca Romano; Calogero Vetro; Ilaria Dulcamare; Cinzia Maugeri; Marina Parisi; Laura Longo; Daniela Cristina Vitale; Francesco Di Raimondo; Filippo Drago
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.639

Review 2.  Novel Mechanisms for Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia.

Authors:  Steven A Manobianco; Tara Rakiewicz; Lindsay Wilde; Neil D Palmisiano
Journal:  Front Oncol       Date:  2022-07-12       Impact factor: 5.738

3.  Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.

Authors:  Esther Schuler; Eva-Maria Wagner-Drouet; Salem Ajib; Gesine Bug; Martina Crysandt; Sabine Dressler; Andreas Hausmann; Daniela Heidenreich; Klaus Hirschbühl; Matthias Hoepting; Edgar Jost; Jennifer Kaivers; Stefan Klein; Michael Koldehoff; Lambros Kordelas; Oliver Kriege; Lutz P Müller; Christina Rautenberg; Judith Schaffrath; Christoph Schmid; Daniel Wolff; Rainer Haas; Martin Bornhäuser; Thomas Schroeder; Guido Kobbe
Journal:  Ann Hematol       Date:  2020-11-16       Impact factor: 3.673
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.